登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C8H18N4O2 · 2HCl
化学文摘社编号:
分子量:
275.18
MDL number:
UNSPSC Code:
12352209
NACRES:
NA.77
Assay:
≥98% (TLC)
Form:
amorphous solid
Storage condition:
OK to freeze, desiccated (hygroscopic)
Quality Segment
assay
≥98% (TLC)
form
amorphous solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
color
white
solubility
water: 50 mg/mL
shipped in
wet ice
storage temp.
−20°C
SMILES string
Cl.Cl.N[C@@H](CCCN=C(N(C)C)N)C(=O)O
InChI
1S/C8H18N4O2.2ClH/c1-12(2)8(10)11-5-3-4-6(9)7(13)14;;/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14);2*1H/t6-;;/m0../s1
InChI key
SYLNVYJOPZWPJI-ILKKLZGPSA-N
General description
A cell-permeable, reversible inhibitor of nitric oxide synthase in vitro (IC50 = 2-3 µM) and in vivo. Causes dose-dependent vasoconstriction and bradycardic effects.
Endogenous reversible inhibitor of nitric oxide synthesis in vitro and in vivo. Causes dose-dependent vasoconstriction and bradycardic effects.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
NOS in vitro
NOS in vitro
Product does not compete with ATP.
Reversible: yes
Target IC50: 2-3 µM inhibiting nitric oxide synthase in vitro
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
Other Notes
Closs, E.I., et al. 1997. Nitric Oxide1, 65.
Faraci, F.M., et al. 1995. Am. J. Physiol.269, H1522.
Gardiner, S.M., et al. 1993. Br. J. Pharmacol. 110, 1457.
Kotani, K., et al. 1992. J. Neurochem.58, 1127.
Vallance, P., et al. 1992. Lancet339, 572.
Faraci, F.M., et al. 1995. Am. J. Physiol.269, H1522.
Gardiner, S.M., et al. 1993. Br. J. Pharmacol. 110, 1457.
Kotani, K., et al. 1992. J. Neurochem.58, 1127.
Vallance, P., et al. 1992. Lancet339, 572.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable